Yarrow Bioscience Inc YARW

Morningstar Rating
$18.60 −1.22 (6.16%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

YARW is trading at a LOCK|&HF?S premium.
Price
$18.80
Fair Value
LOCK|.H$>t#%
Uncertainty
LOCK|rc m#?$F
1-Star Price
LOCK|.wG$Fzg
5-Star Price
LOCK|.>$&B>
Economic Moat
LOCK|!C
Capital Allocation
—

Trading Information

Previous Close Price
$19.82
Day Range
$18.40–20.16
52-Week Range
$0.32–44.28
Bid/Ask
$16.25 / $29.75
Shares Outstanding
9.30M
Market Cap
$156.96M
Volume/Avg
99,832 / 412,433

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
—
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
—
Total Number of Employees
—

Valuation

Metric
YARW
Price/Earnings (Normalized)
—
Price/Book Value
—
Price/Sales
—
Price/Cash Flow
—
Price/Earnings
No chart available

Financial Strength

Metric
YARW
Quick Ratio
14.87
Current Ratio
15.26
Interest Coverage
—
Quick Ratio
YARW

Profitability

Metric
YARW
Return on Assets (Normalized)
—
Return on Equity (Normalized)
—
Return on Invested Capital (Normalized)
—
Return on Assets
No chart available

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|%wj?YzLOCK|!&^!$$123B
Moderna Inc
MRNA
LOCK|?GBpb@LOCK|@Z!$86B
Regeneron Pharmaceuticals Inc
REGN
LOCK|hJTmC@LOCK|%snZl$78B
argenx SE ADR
ARGX
LOCK|@ql$!t<LOCK|@p$50B
BeOne Medicines Ltd ADR
ONC
LOCK|g!&c%$LOCK|zW<$41B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|G&SVVMNLOCK|r@$jZ$30B
Royalty Pharma PLC Class A
RPRX
LOCK|DcqCdWS$LOCK|#b^<$25B
BioNTech SE ADR
BNTX
LOCK|gM@TSJsLOCK|@@$22B
Incyte Corp
INCY
LOCK|>rkDcF%LOCK|>m>$22B
Jazz Pharmaceuticals PLC
JAZZ
LOCK|>!^y!@<LOCK|k$&$14B

Sponsor Center